

RealRate

PHARMACEUTICAL 2022











RealRate

PHARMACEUTICAL 2022



Lantern Pharma Inc. Rank 27 of 466

The relative strengths and weaknesses of Lantern Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lantern Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Lantern Pharma Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 290%, being 212% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	72,716
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,326
Liabilities, Non-Current	53
Other Assets	1,204
Other Compr. Net Income	0
Other Expenses	12,592
Other Liabilities	0
Other Net Income	228
Other Revenues	0
Property and Equipment	30
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	73,950
Liabilities	2,379
Expenses	12,592
Revenues	0
Stockholders Equity	71,571
Net Income	-12,363
Comprehensive Net Income	-12,363
Economic Capital Ratio	290%

